

## **Latest addition to Cook Medical's Leg Therapies product line, Zilver @ PTX @ Drug-Eluting Peripheral Stent, is designed to treat PAD in the superficial femoral artery (SFA)**

The Associated Press

BLOOMINGTON, Ind.--(BUSINESS WIRE)--May 21, 2012-- Cook Medical, a world leader in minimally invasive medical technologies, has launched a first-of-its-kind drug-eluting peripheral stent in Australia, the Zilver(R) PTX(R) Drug-Eluting Peripheral Stent. The device, which is available in more than 50 countries, is registered with Australia's Therapeutic Goods Administration (TGA) and is now available to physicians there as a new treatment option for patients with lesions in the SFA, the largest artery in the leg.

"It's really exciting to me that Cook Medical is bringing drug-eluting device technology to the periphery because this is a brand new treatment option for a condition that affects millions worldwide," said Rob Lyles, vice president and global leader of Cook Medical's Peripheral Intervention division. "Many physicians now are convinced drug elution is the future of treating lesions in the leg arteries, and our Australian Zilver PTX launch is an important step in Cook's efforts to bring this advanced treatment to patients and physicians around the world." The Zilver PTX Drug-Eluting Peripheral Stent offers physicians treating PAD in the SFA the combination of mechanical support via stenting with the drug paclitaxel to reduce the risk of restenosis (renarrowing) within the vessel.

The Zilver PTX Drug Eluting Stent is under U.S. Food and Drug Administration review and is not available for sale in the United States. It received CE Mark approval for sale in the European Union in August 2009 and is now approved in Japan, Brazil and other international markets.

About Cook Medical A global leader in medical devices, Cook Medical creates clinical solutions benefitting millions of patients worldwide. Today, we combine medical devices, drugs, biologic grafts and cell therapies across more than 16,000 products serving more than 40 medical specialties. Founded in 1963 by a visionary who put patient needs first, Cook is a family-owned global corporation with more than 10,000 employees. For more information, visit [www.cookmedical.com](http://www.cookmedical.com). Follow Cook Medical on Twitter and LinkedIn and @cookvascular.

CONTACT: Cook Medical David McCarty, 812-339-2235, ext. 2387 Director, Public Relations [dave.mccarty@cookmedical.com](mailto:dave.mccarty@cookmedical.com) or Racepoint Group, Inc.

Cheri Keith, 781-487-4672 [ckeith@racepointgroup.com](mailto:ckeith@racepointgroup.com) KEYWORD: UNITED STATES ASIA PACIFIC NORTH AMERICA INDIANA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL OTHER HEALTH GENERAL

## **Latest addition to Cook Medical's Leg Therapies product line, Zilver @ PTX**

Published on Medical Design Technology (<http://www.mdtmag.com>)

---

HEALTH SOURCE: Cook Medical Copyright Business Wire 2012 PUB: 05/21/2012

09:00 AM/DISC: 05/21/2012 09:00 AM

<http://www.businesswire.com/news/home/20120521005763/>

### **Source URL (retrieved on 10/30/2014 - 2:26pm):**

<http://www.mdtmag.com/news/2012/05/latest-addition-cook-medicals-leg-therapies-product-line-zilver-ptx-drug-eluting-peripheral-stent-designed-treat-pad-superficial-femoral-artery-sfa>